Percutaneous vertebroplasty and spinal cord compression: a case report

Morghen, Ilaria; Borrelli, Massimo; Saletti, Andrea; Zoppellari, Roberto

doi:10.3941/jrcr.v3i3.108

Cited by 3 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on a meta-analysis, the clinical efficacy showed that OVCFs patients who underwent VAP treatment were 22% less likely to die at up to 10 years than those receiving nonsurgical treatment [106]. However, the prevalence of severe complications related to VAP could be as high as 12.5-36.8% [108][109][110][111][112]. The most common complications encountered are cement leakage and new OVCFs at the adjacent level.…”

Section: Surgery Treatmentmentioning

confidence: 99%

Drug Therapeutics of Osteoporosis, Vertebral Fracture and Nonunion

Gou,

Chang

2023

Osteoporosis - Pathophysiology, Diagnosis, Management and Therapy

View full text Add to dashboard Cite

Osteoporosis management is effective in decreasing vertebral fracture risk. The assessment of vertebral fracture risk is used to identify patients with high fracture risk for anti-osteoporotic treatment, especially for those who have not yet fractured. Several pharmacological agents are available to lower vertebral fracture risk by reducing bone resorption or/and stimulating bone formation. Aside from surgical treatment for fresh vertebral fracture or fracture nonunion in elderly patients, recent studies indicated that management of osteoporosis plays a vital role in boosting vertebral fracture union, preventing progressive vertebral collapse and decreasing the refracture risk. In this chapter, we focus on the treatment of osteoporosis, acute vertebral fractures and nonunion, as well as the evaluation of clinical efficacy by bone quality and bone turnover markers after treatment.

show abstract

Section: Surgery Treatmentmentioning

confidence: 99%

Drug Therapeutics of Osteoporosis, Vertebral Fracture and Nonunion

Gou,

Chang

2023

Osteoporosis - Pathophysiology, Diagnosis, Management and Therapy

View full text Add to dashboard Cite

show abstract

“…Another challenge is that VAP is not suitable for patients with surgical contraindications 19 . In addition, the prevalence of severe complications related to VAP could be as high as 12.5%–36.8% 20 , 21 , 22 , 23 , 24 .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Recombinant Human Parathyroid Hormone versus Vertebral Augmentation Procedure on Patients with Acute Osteoporotic Vertebral Compression Fracture

Gou

Zhao

et al. 2022

Orthopaedic Surgery

View full text Add to dashboard Cite

Objective: Although widely used in clinical practice, vertebral augmentation procedure (VAP) for osteoporotic vertebral compression fracture (OVCF) is not supported. Recently, the effect of recombinant human parathyroid hormone (1-34) (rhPTH) has been paid great attention for its efficacy in anti-osteoporosis and bone union. This study aims to explore the outcome of rhPTH on acute OVCF and compare it with VAP to clarify its therapeutic advantages. Methods:The retrospective study comprised 71 acute OVCF patients from January 2015 to March 2020: 22 received rhPTH treatment (rhPTH group) and 49 underwent VAP (VAP group). The rhPTH group was 15 women and seven men with an average of 76.18 years, and the VAP group were 35 women and 14 men with an average of 73.63 years. The thoracic/lumbar vertebrae were 14/8 in the rhPTH group and 29/20 in the VAP group. The average follow-up period was 14.05 months in the rhPTH group and 13.82 months in the VAP group. The two groups were assessed regarding the visual analog score (VAS), Oswestry Disability Index (ODI), OVCF bone union, bone mineral density (BMD), kyphotic angle (KA), anterior and posterior border height (ABH and PBH, respectively), adverse events and the health-related quality of life assessed by short form-36 health survey scores (SF-36). Categorical variables were analyzed by chisquare test and continuous variables between groups were analyzed by independent samples t-test or Mann-Whitney U test according to the normality.Results: During the follow-up, the VAS was significantly lower in the rhPTH group than in the VAP group at month 3 (0.39 AE 0.6 vs 0.68 AE 0.651) (p = 0.047), month 6 (0.45 AE 0.60 vs 2.18 AE 1.22) (p < 0.001), and month 12 (0.45 AE 0.60 vs 2.43 AE 1.49) (p < 0.001). At month 12, the ODI was significantly lower in the rhPTH group (18.59 AE 3.33%) than in the VAP group (28.93 AE 16.71%) (p < 0.001). Bone bridge was detected on sagittal computed tomography images of all fractured vertebrae in the rhPTH group. The BMD was significantly higher in the rhPTH group (87.66 AE 5.91 Hounsfield units [HU]) than in the VAP group (68.15 AE 11.32HU) (p < 0.001). There were no significant differences in the changes in KA, ABH, and PBH between groups (all p > 0.05). The incidence of new OVCF was significantly lower in the rhPTH group than in the VAP group (p = 0.042). All scores of SF-36 were significantly higher in the rhPTH group than in the VAP group (all p < 0.05). Conclusion:In acute OVCF patients, rhPTH was better than VAP in increasing spinal BMD to promote OVCF healing, reduce new OVCF, and improve back pain, physical ability, and health-related quality of life.

show abstract

Current status and challenges of percutaneous vertebroplasty (PVP)

et al. 2022

View full text Add to dashboard Cite

A narrative review regarding percutaneous vertebroplasty (PVP) for osteoporotic vertebral fracture (OVF) is provided herein, addressing the epidemic of OVF in Japan, the latest response to the criticism of PVP for OVFs, the indications and potential risks of PVP for OVFs, and a future perspective for PVP. Each year in Japan, approximately 32,000 patients aged 55 years or older suffer from chronic low back pain for several months to several years due to a compression fracture. PVP is one of the surgical treatments for an OVF, and it is less invasive compared to the traditional open surgery. PVP is suitable for OVF patients who have difficulty walking as assessed by the modified Yokoyama’s activities of daily living (ADL) scoring system, and for patients with Kummell's disease diagnosed by CT and MRI examinations. Serious adverse events related to PVP occur in 1.1–3.3% of the cases, but direct deaths from PVP are extremely rare at less than 1%. Recent studies demonstrated that OVF patients treated with PVP are less likely to die after the treatment than non-surgically treated patients, which conflicts with the Cochran reviews’ conclusion not supporting PVP for OVFs. Novel robotic systems and procedure-support devices are being developed, providing a next step toward fully automated PVP procedures.

show abstract

Percutaneous vertebroplasty and spinal cord compression: a case report

Cited by 3 publications

References 2 publications

Drug Therapeutics of Osteoporosis, Vertebral Fracture and Nonunion

Drug Therapeutics of Osteoporosis, Vertebral Fracture and Nonunion

Efficacy of Recombinant Human Parathyroid Hormone versus Vertebral Augmentation Procedure on Patients with Acute Osteoporotic Vertebral Compression Fracture

Current status and challenges of percutaneous vertebroplasty (PVP)

Contact Info

Product

Resources

About